Preclinical pharmacologic studies showed that after chronic treatment of tumor-bearing animals with namodenoson, A3AR was downregulated shortly after treatment; however, A3AR levels resumed pretreatment levels after a few hours [9]. The gene discussed is ADORA3; the disease is neoplasm.